Eli Lilly has become one of the most impressive pharmaceutical companies in the world, supported by major franchises across diabetes, obesity and other serious diseases.
The enormous demand for GLP-1 treatments has transformed Lilly's growth outlook, while its broader research pipeline provides opportunities extending well beyond today's blockbuster products. The obesity market alone could remain one of the pharmaceutical industry's largest opportunities for many years.
The biggest concern is valuation. At around $1,200, investors are already pricing in considerable future success, so even a great company can experience meaningful corrections.
Overall: LLY combines blockbuster medicines, powerful structural growth and an impressive pipeline. The stock isn't cheap, but the underlying business deserves its premium reputation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
